Interest of a Highly Cross-linked Polyethylene Acetabular Component Doped With Vitamin E in Total Hip Arthroplasty of the Young and Active Subject

Launched by GCS RAMSAY SANTÉ POUR L'ENSEIGNEMENT ET LA RECHERCHE · Dec 14, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at a special type of hip replacement surgery for younger and more active patients. It focuses on using a particular material for the hip socket, which is made of highly cross-linked polyethylene and contains vitamin E. Researchers want to see if this new material can improve the results of total hip arthroplasty, which is the medical term for hip replacement surgery, by making the joint last longer and work better.

To participate in this study, you need to be between the ages of 18 and 65 and have been advised by your doctor that you need a hip replacement. It’s important that you understand the study and agree to participate. However, if you have had previous hip surgery, certain medical conditions, or if you are pregnant or breastfeeding, you may not be eligible. If you join the study, you will receive the new hip component and will be asked to attend follow-up visits to monitor your progress. This trial is currently recruiting participants, and your involvement could help improve future treatments for hip problems.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient aged 18 to 65 years,
• • Who have signed their consent to participate in the study,
• • For whom an indication for total hip arthroplasty has been given
• Exclusion Criteria:
• • History of hip surgery
• • Indication for a dual mobility prosthesis (obese patient, dynamic spino-pelvic anomaly)
• • Hip dysplasia
• • Inflammatory rheumatic disease or any other progressive concomitant condition that may impact the patient's vital or functional prognosis
• • Sequelae of neurological disease or stroke
• • Pregnant or breastfeeding women
• • Mental deficiency or any other reason that may hinder the understanding or the strict application of the protocol
• • Patient likely not to return for follow-up visits
• • Patient already included in another therapeutic study protocol
• • Patient under court protection, guardianship or curatorship.